The conceptus is an allograft that expresses paternal antigens yet is not rejected. Erlebacher et al. (2007) visualized maternal CD4+ and CD8+ T cell responses to a defined fetal antigen (membrane-bound ovalbumin expressed by the conceptus) and found that maternal T cells sense the fetus exclusively through indirect antigen presentation (uptake of shed antigen by maternal antigen-presenting cells), that indirectly reactive T cells are poorly primed and clonally deleted, and that even artificially activated antigen-specific cytotoxic T lymphocytes fail to kill antigen-expressing concepti. The paper left six linked mechanistic questions open. Subsequent work substantially resolved two of them (the basis of absent direct recognition and the form in which conceptus antigen reaches the maternal circulation) and made deep inroads into the tolerance mechanisms — fetal-antigen-specific regulatory T cells, inhibitory ligand pathways, and a newly discovered trophoblast-glycan/Siglec axis that suppresses antigen-specific B cells. The surviving open core asks for the integrated, in vivo molecular mechanisms that keep maternal T cell responses to trophoblast-derived antigens non-immunogenic, that prevent effector CTLs from destroying the placenta, that mediate paradoxical antigen-specific early pregnancy loss, and which of these mechanisms operate in human pregnancy and its complications.

Background

How the fetus escapes rejection by the maternal immune system has been called one of the central unsolved questions in transplantation immunology. The placenta is lined by trophoblasts — fetal epithelial cells that are in direct contact with maternal blood and with immune cells in the uterine lining (the decidua). In transplantation immunology, T cell recognition of foreign (allogeneic) major histocompatibility complex (MHC) molecules — the highly polymorphic cell-surface proteins that display peptides to T cells — occurs by two routes: direct allorecognition, where recipient T cells engage intact donor MHC molecules on donor antigen-presenting cells (APCs), and indirect allorecognition, where donor proteins are taken up, processed, and presented as peptides on self MHC by recipient APCs. Directly alloreactive T cells outnumber indirectly reactive ones by more than ten to one and drive acute transplant rejection. Because directly alloreactive T cells respond to intact foreign MHC rather than a specific peptide, they are best studied with T cell receptor (TCR) transgenic tools: mice in which most T cells carry a receptor of known specificity (e.g., the OT-I and OT-II receptors for ovalbumin peptides, or the BM3 receptor for the MHC class I molecule H-2K^b). Erlebacher and colleagues used adoptive transfer of OT-I (CD8+) and OT-II (CD4+) cells into females impregnated by males carrying an Act-mOVA transgene, which directs a membrane-bound form of ovalbumin (mOVA) to the conceptus, most strongly in trophoblast giant cells (specialized large endocrine cells of the rodent placenta) and endovascular trophoblasts (fetal cells that invade and line maternal blood vessels) at the maternal/fetal interface. Regulatory T cells (Tregs) are a Foxp3-lineage CD4+ subset that suppresses other immune cells; indoleamine 2,3-dioxygenase (IDO) is a placental enzyme that catabolizes tryptophan and was an early candidate tolerogenic mechanism; PD-L1 is an inhibitory ligand expressed at the maternal/fetal interface that engages the PD-1 receptor on activated T cells. Decidual natural killer (NK) cells — innate lymphocytes that are the most abundant leukocytes at the interface in early gestation — recognize stressed or abnormal cells via activating receptors (in humans, killer immunoglobulin-like receptors, KIR, which sense fetal HLA-C molecules) rather than by adaptive antigen specificity. Erlebacher et al. (2007) established three simultaneously acting tiers of protection: (1) maternal T cells never directly recognize fetal MHC (directly alloreactive BM3 cells remain ignorant of H-2K^b concepti), so awareness occurs only via the minor indirect pathway; (2) indirectly reactive CD4+ and CD8+ T cells are poorly primed and undergo clonal deletion, in contrast to indirectly alloreactive T cells primed by organ transplants; and (3) even antigen-specific cytotoxic T lymphocytes (CTLs) deliberately activated during pregnancy — using an antibody against CD40, a costimulatory receptor that activates antigen-presenting cells, together with poly(I:C), a synthetic double-stranded RNA that mimics viral infection and acts as an adjuvant — cannot kill mOVA-expressing concepti. Each tier raised its own mechanistic question, and the paper additionally flagged a paradox: several models show fetal loss that is specific to allogeneic (as opposed to syngeneic) mating combinations as early as embryonic day 9.5, before systemic presentation of conceptus antigen begins — so some effector other than conventionally primed T cells must discriminate self from non-self in early allospecific abortion, with decidual NK cells, stress-induced ligands, and bystander inflammation as candidates. Later work added a key structural insight: trophoblast-derived proteins, unlike fetal blood cell antigens such as the Rhesus D (Rh(D)) red-blood-cell antigen, carry heavily sialylated N-linked glycans; sialic acid residues act as 'self' signals for Siglec inhibitory receptors (sialic acid-binding immunoglobulin-like lectins; e.g., CD22 on B cells, which signals through the Lyn tyrosine kinase), a glycan axis that suppresses antigen-specific maternal B cells and, partly, the CD4 T cells they present antigen to.

Problem Statement

As posed by Erlebacher et al. (2007), the problem is to determine, at the level of antigen-specific maternal lymphocytes, why the allogeneic conceptus is not rejected — and, conversely, what mediates antigen-specific early pregnancy loss. Concretely, the interlinked questions are: (1) the cellular and molecular basis for the absence of direct maternal T cell recognition of the conceptus (passenger-APC paucity, low MHC class I expression, or additional mechanisms) — now largely answered by decidual dendritic-cell entrapment and cell-free antigen transport, with only residual cases open; (2) the precise mechanisms producing clonal deletion and defective priming of indirectly reactive T cells — the relative and integrated roles of fetal-antigen-specific regulatory T cells, inhibitory ligands such as PD-L1, pregnancy hormones and conceptus-derived immunoregulatory factors, absence of inflammatory costimulation, trophoblast-antigen glycosylation acting through inhibitory Siglec receptors, and the unexpectedly B-cell-exclusive presentation of trophoblast antigen; (3) the mechanistic basis for the inability of activated antigen-specific CTLs to kill antigen-expressing concepti — insufficient placental peptide-MHC display, physical or molecular barriers to CTL access, active local inhibitory signals, and the observed exhaustion/hypofunction programming of fetal-antigen-specific CD8 T cells; (4) the molecular form in which conceptus antigen is released into maternal blood and presented to maternal APCs (resolved for model antigens as cell-free, sialylated trophoblast glycoprotein; open for bona fide trophoblast and cytoplasmic antigens); (5) identification of the effector mechanisms — decidual NK cells, stress-induced ligand recognition, bystander or innate activation, or antibody/complement — that mediate allospecific fetal damage occurring before widespread antigen presentation, and whether villitis of unknown etiology in human placentas is the manifestation of true maternal anti-placental rejection; and (6) which of these mechanisms operate in human pregnancy and its complications such as recurrent early pregnancy failure. A complete answer must (i) provide in vivo mechanistic evidence that accounts for the coexistence of tolerance to trophoblast antigens with immunization to fetal blood cell antigens, (ii) reproduce or rule out antigen-specific placental rejection, (iii) identify the effector pathway of allospecific early pregnancy loss, and (iv) establish which of these mechanisms are operative in humans. These four criteria are the completion test, and the numbered questions are a decomposition of it rather than additional required parts; where a numbered question lists candidate mechanisms, that list names the class to be characterized and integrated rather than a checklist each member of which is separately mandatory. Questions (1) and (4) are background context; any residual cases within them are weighed through criteria (i)–(iv) rather than graded on their own.

References

  1. Erlebacher A, Vencato D, Price KA, Zhang D, Glimcher LH. 'Constraints in antigen presentation severely restrict T cell recognition of the allogeneic fetus.' Journal of Clinical Investigation, 2007;117(5):1399-1411. doi:10.1172/jci28214. https://doi.org/10.1172/jci28214
  2. Collins MK, Tay C-S, Erlebacher A. 'Dendritic cell entrapment within the pregnant uterus inhibits immune surveillance of the maternal/fetal interface in mice.' Journal of Clinical Investigation, 2009;119(7):2062-2073. doi:10.1172/jci38714. https://doi.org/10.1172/jci38714
  3. Tay C-S, Tagliani E, Collins MK, Erlebacher A. 'Cis-Acting Pathways Selectively Enforce the Non-Immunogenicity of Shed Placental Antigen for Maternal CD8 T Cells.' PLoS ONE, 2013;8(12):e84064. doi:10.1371/journal.pone.0084064. https://doi.org/10.1371/journal.pone.0084064
  4. Rowe JH, Ertelt JM, Xin L, Way SS. 'Pregnancy imprints regulatory memory that sustains anergy to fetal antigen.' Nature, 2012;490(7418):102-106. doi:10.1038/nature11462. https://doi.org/10.1038/nature11462
  5. Rowe JH, Ertelt JM, Aguilera MN, Farrar MA, Way SS. 'Foxp3+ regulatory T cell expansion required for sustaining pregnancy compromises host defense against prenatal bacterial pathogens.' Cell Host & Microbe, 2011;10(1):54-64. doi:10.1016/j.chom.2011.06.005. https://doi.org/10.1016/j.chom.2011.06.005
  6. Xin L, Ertelt JM, Rowe JH, Jiang TT, Kinder JM, Chaturvedi V, Elahi S, Way SS. 'Cutting Edge: Committed Th1 CD4+ T Cell Differentiation Blocks Pregnancy-Induced Foxp3 Expression with Antigen-Specific Fetal Loss.' Journal of Immunology, 2014;192(7):2970-2974. doi:10.4049/jimmunol.1302678. https://doi.org/10.4049/jimmunol.1302678
  7. Samstein RM, Josefowicz SZ, Arvey A, Treuting PM, Rudensky AY. 'Extrathymic Generation of Regulatory T Cells in Placental Mammals Mitigates Maternal-Fetal Conflict.' Cell, 2012;150(1):29-38. doi:10.1016/j.cell.2012.05.031. https://doi.org/10.1016/j.cell.2012.05.031
  8. Rizzuto G, Brooks JF, Tuomivaara ST, McIntyre TI, Ma S, Rideaux D, Zikherman J, Fisher SJ, Erlebacher A. 'Establishment of fetomaternal tolerance through glycan-mediated B cell suppression.' Nature, 2022;603(7901):497-502. doi:10.1038/s41586-022-04471-0. https://doi.org/10.1038/s41586-022-04471-0
  9. Rizzuto G, Erlebacher A. 'Trophoblast antigens, fetal blood cell antigens, and the paradox of fetomaternal tolerance.' Journal of Experimental Medicine, 2022;219(5):e20211515. doi:10.1084/jem.20211515. https://doi.org/10.1084/jem.20211515
  10. Kinder JM, Turner LH, Stelzer IA, Miller-Handley H, Burg A, Shao T-Y, Pham G, Way SS. 'CD8+ T Cell Functional Exhaustion Overrides Pregnancy-Induced Fetal Antigen Alloimmunization.' Cell Reports, 2020;31(12):107784. doi:10.1016/j.celrep.2020.107784. https://doi.org/10.1016/j.celrep.2020.107784
  11. Lewis EL, Xu R, Beltra J-C, Ngiow SF, Cohen J, Telange R, Crane A, Sawinski D, Wherry EJ, Porrett PM. 'NFAT-dependent and -independent exhaustion circuits program maternal CD8 T cell hypofunction in pregnancy.' Journal of Experimental Medicine, 2022;219(1):e20201599. doi:10.1084/jem.20201599. https://doi.org/10.1084/jem.20201599
  12. Aluvihare VR, Kallikourdis M, Betz AG. 'Regulatory T cells mediate maternal tolerance to the fetus.' Nature Immunology, 2004;5(3):266-271. doi:10.1038/ni1037. https://doi.org/10.1038/ni1037
  13. Guleria I, Khosroshahi A, Ansari MJ, Habicht A, Azuma M, Yagita H, Noelle RJ, Coyle A, Mellor AL, Khoury SJ, Sayegh MH. 'A critical role for the programmed death ligand 1 in fetomaternal tolerance.' Journal of Experimental Medicine, 2005;202(2):231-237. doi:10.1084/jem.20050019. https://doi.org/10.1084/jem.20050019
  14. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL. 'Prevention of allogeneic fetal rejection by tryptophan catabolism.' Science, 1998;281(5380):1191-1193. doi:10.1126/science.281.5380.1191. https://doi.org/10.1126/science.281.5380.1191
  15. Suah AN, Tran D-KV, Khiew SHW, Andrade MS, Pollard JM, Jain D, Young JS, Yin D, Chalasani G, Alegre M-L, Chong AS. 'Pregnancy-induced humoral sensitization overrides T cell tolerance to fetus-matched allografts in mice.' Journal of Clinical Investigation, 2021;131(1):e140715. doi:10.1172/jci140715. https://doi.org/10.1172/jci140715
  16. Hiby SE, Apps R, Sharkey AM, Farrell LE, Gardner L, Mulder A, Claas FHJ, Walker JJ, Redman CC, Morgan L, Tower C, Regan L, Moore GE, Carrington M, Moffett A. 'Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2.' Journal of Clinical Investigation, 2010;120(11):4102-4110. doi:10.1172/JCI43998. https://doi.org/10.1172/JCI43998
  17. Thiele K, Urbschat C, Amambay Riquelme JI, Ahrendt LS, Wöhrle R, Schepanski S, Eckert JJ, Becht E, Qi M, Alawi M, Becker M, Gagliani N, Mittrücker H-W, Diemert A, Arck PC. 'Pregnancy-acquired memory CD4+ regulatory T cells improve pregnancy outcome in mice.' Nature Communications, 2025;16(1):6522. doi:10.1038/s41467-025-61572-w. https://doi.org/10.1038/s41467-025-61572-w